With the FDA's Jan. 16 action date approaching for MannKind Corp.'s inhaled insulin Afresa, Wall Street grows less and less excited about the prospects for anything actually happening, given the agency's "glacial pace" - in the words of analysts at Hapoalim Securities - and the lack of an advisory panel for the Exubera-spooked candidate. Read More
